Wikipedia

Telmisartan/hydrochlorothiazide

Telmisartan/hydrochlorothiazide, sold under the brand name Micardis HCT among others, is a fixed-dose combination medication used to treat high blood pressure.[2] It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic.[2] It may be used if telmisartan by itself is not sufficient.[5] It is taken by mouth.[5]

Telmisartan/hydrochlorothiazide
Combination of
TelmisartanAngiotensin II receptor antagonist
HydrochlorothiazideThiazide diuretic
Clinical data
Trade namesMicardisPlus, Micardis HCT, PritorPlus, others
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[1]
  • US: ℞-only[2]
  • EU: Rx-only[3][4]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H38ClN7O6S2
Molar mass812.36 g·mol−1
3D model (JSmol)
  • CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
  • InChI=1S/C33H30N4O2.C7H8ClN3O4S2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39);1-2,10-11H,3H2,(H2,9,12,13)
  • Key:OZCVMXDGSSXWFT-UHFFFAOYSA-N
  (verify)

Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness.[2] Severe side effects may include kidney problems, electrolyte problems, and allergic reactions.[2] Use during pregnancy may harm the baby.[2] Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys' ability to retain water.[2]

The combination was approved for medical use in the United States in November 2000,[6][7] and in the European Union in April 2002.[3][4] The combination is on the World Health Organization's List of Essential Medicines.[8] It is available as a generic medication.[5]

References

edit
  1. ^ "MicardisPlus 40 mg/12.5 mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 28 May 2020. Retrieved 23 November 2020.
  2. ^ a b c d e f g "Micardis HCT- telmisartan and hydrochlorothiazide tablet". DailyMed. 27 August 2020. Retrieved 4 October 2020.
  3. ^ a b "MicardisPlus EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 October 2020.
  4. ^ a b "PritorPlus EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 October 2020.
  5. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 178. ISBN 9780857113382.
  6. ^ "Drug Approval Package: Micardis HCT (telmisartan/hydrochlorothiazide) NDA #021162". U.S. Food and Drug Administration (FDA). 11 March 2004. Retrieved 4 October 2020.
  7. ^ "Hydrochlorothiazide and telmisartan Uses, Side Effects & Warnings". Drugs.com. Retrieved 29 October 2019.
  8. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Telmisartan/hydrochlorothiazide&oldid=1240676119"